Auxilium Pharmaceuticals (AUXL) Gains Following Comments from RBC Capital
Tweet Send to a Friend
RBC Capital maintained an Outperform rating on Auxilium Pharmaceuticals (NASDAQ: AUXL) with a price target of $28. Analyst Michael J ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
